Member Info for Marty130

Perhaps sold their holding to another fund..

They're are already listed on the OTC..

Hearing where?

I can't find the evidence to prove that.

And after that!!!!!!!!!!!! SP will be let loose!!!

That was my thinking also, the BoD would be taking that into account, should they not sell us out for chip paper..

Volumes are through the roof, a classic signs of a take over. MM can't keep this pegged for much longer..

Last time the SP went up by 280%, so I imagine the SP will behave similarly..

Https://investors.renalytix.com/news-release/holdings-in-company-70/

07/24

Yes, I will be be adding more today..

Definitely someone taking a position.. Just hope the BoD don't sell this on the cheap.

At least north of 50p.

Than offer this time has to be much higher than previous one, as the company is now much more valuable.

Last time a T/O happened, this went up by 300%.

Peace prize or medicine prize?

So is it any good for Multiple Sclerosis?

Shares

Updated: 04/03/2024

Renalytix shares soar after announcing takeover approach

By

UK Investor Magazine

04/03/2024

Renalytix, an artificial intelligence-enabled diagnostics company focused on kidney disease, has received an unsolicited acquisition approach from a large, publicly-listed strategic diagnostics company.

In response, Renalytix has commenced a formal sale process to review all available options, including a potential sale of the company or assets. Renalytix said it had not yet received a formal offer.

Renalytix shares were 50% higher at the time of writing.

In February, Renalytix announced the US Centers for Medicare and Medicaid Services published a draft Local Coverage Determination for the Renalytix KidneyIntelX and kidneyintelX.dkd testing at a price of $950 per test. The announcement was followed by further news the coverage of the testing had been expanded to any US government agency conducting kidney testing.

Should the takeover be completed, Renalytix will be the latest UK company to be taken over amid low UK equity valuations.

Renalytix is one of AIMs best performing stocks of 2024 so far with a gain of 280%.

Latest News

More Articles Like This

AIM movers: EnSilica hit by delays and ex-dividends

FTSE 100 dragged down by Whitbread as US banks impress

Eco Buildings shares surge again as global growth strategy outlined

Whitbread shares sink amid operating loss and falling revenue

Get in Touch

Advertise with us

Contact

Legals

Terms & Conditions

Events Terms & Conditions

Privacy Policy

Cookies

Disclaimer & Disclosure

My account

Become Member

Login

Account

Latest Stories

AIM movers: EnSilica hit by delays and ex-dividends

FTSE 100 dragged down by Whitbread as US banks impress

Eco Buildings shares surge again as global growth strategy outlined

Ail Arian: Enabling the creation of Circular Electronics

Whitbread shares sink amid operating loss and falling revenue

© UK Investor Group UK Investor and UK Investor Magazine are registered trademarks of UK Investor Group Ltd (09932115) | All rights reserved

RNS Number : 9865A

Renalytix PLC

20 August 2024

Renalytix plc

("Renalytix" or the "Company")

Termination of Formal Sale Process

LONDON and NEW YORK, 20 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provides the following update in respect of its Formal Sale Process.

As announced on 4 March 2024, the Company commenced its Formal Sale Process after receiving an unsolicited approach from a large and well-capitalised publicly listed strategic diagnostics company, which was evaluating an acquisition of the entire issued, and to be issued, share capital of the Company.

The Board of the Company (the "Board") has determined that based on outreach, dialogue and discussions to date, it does not believe there is a realistic prospect of an offer for the issued, and to be issued, share capital of Renalytix being forthcoming in the near term. As such, the Board has decided to terminate the Formal Sale Process under the Takeover Code and the Company is therefore no longer in an Offer Period.

The Company confirms that it is in advanced discussions with key stakeholders of the business, who have indicated their support for management to achieve the Company's goals of the refreshed business plan, with focused expenditure and investment alongside reduced operating costs, and a suitable capital structure and funding. The Company will continue to assess options to maximise value for its shareholders and further updates will be made as appropriate.

Having achieved significant milestones for the business, including FDA approval for KidneyIntelX, and a final Medicare coverage determination for the Company's kidneyintelX.dkd testing with an established price of $950 per test, Renalytix has made positive progress operationally this year in addition to the financings completed earlier in 2024. The Company believes that the total addressable market opportunity for KidneyIntelX provides potential for significant growth in revenues over the next 3 years, subject to funding and continued development of commercial partnerships.

Subsequent to the financings that were successfully completed earlier in 2024, the Company has cash runway extending into Q4 2024, with an unaudited cash position of $4.7m as at 30 June 2024.

For further information, please contact:

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker and Sole Financial & Rule 3 Adviser)

Tel: 020 7710 7600

Nicholas Moore / Nick Harland / Ben Good

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

CapComm Partners

Peter DeNardo

I have watched that..